ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1995-4484-2015-596-602
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune rheumatic disease characterized by chronic inflammation of the synovial membrane and a wide range of extra-articular (systemic) manifestations. The main goal of RA therapy is to achieve low disease activity or clinical remission. Power Doppler (PD) ultrasonography (USG) can significantly distinguish between active synovitis (hypervascularization of the synovial membrane) and inactive synovial proliferation.
Objective: to investigate the association between the ultrasonic signs of active inflammation and the clinical and laboratory parameters of disease activity in patients with RA.
Subjects and methods. The investigation included RA patients followed up at the V.A. Nasonova Research Institute of Rheumatology within the first Russian strategic study of pharmacotherapy for RA – REMARCA (Russian invEstigation of MethotrexAte and biologicals for eaRly aCtive Arthritis). A total of 105 RA patients (mean age 51 years), among whom 80% were rheumatoid factor (RF)-positive and 75% were anti-cyclic citrullinated peptide (ACCP)-positive, were examined. In all the patients, methotrexate (metoject, MEDAC, Germany) as the first diseasemodifying anti-rheumatic drug was subcutaneously injected in an initial dose of 10 mg/week with its rapid escalation up to 20–25 mg/week. Then the therapy was added by biologicals as the need arose. The clinical and laboratory parameters were analyzed immediately before and then 12, 24, 36, and 48 weeks following treatment. Therapeutic efficacy was evaluated using the European League Against Rheumatism (EULAR) criteria and activity indices (DAS28, CDAI, and SDAI). USG of eight articular areas (the wrist, second and third metacarpophalangeal, second and third proximal interphalangeal, second and fifth metatarsophalangeal articulations) in the hand and foot of the clinically dominant side was carried out in all the patients prior to treatment and at 12, 24, 36, and 48 weeks after its initiation. Semiquantitative gray-scale (GS) assessment and PD USG were performed according to the OMERACT criteria.
Results and discussion. Weak correlations were found between USG parameters and DAS28, SDAI, and CDAI. After 48-week therapy, the signs of active synovitis were absent in 54 patients and persisted in 51, as evidenced by PD USG. The differences in clinical, laboratory, and ultrasonic parameters were analyzed in relation to USG evidence for active inflammation following 48 weeks of treatment. There were significant differences in GS and PD scores throughout the follow-up period; there were also differences in C-reactive protein levels at 12 and 48 weeks of therapy. No differences were found in clinical activity indices.
Conclusion. The investigation provides support for the important role of USG in assessing the activity of synovitis in RA.
About the Authors
O. G. AlekseevaRussian Federation
M. V. Severinova
Russian Federation
N. V. Demidova
Russian Federation
E. N. Aleksandrova
Russian Federation
A. A. Novikov
Russian Federation
E. L. Luchikhina
Russian Federation
D. E. Karateev
Russian Federation
A. V. Volkov
Russian Federation
E. L. Nasonov
Russian Federation
References
1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290–331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In.: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290–331].
2. Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical Recommendations]. Moscow: GEOTAR-Media; 2010].
3. Smolen JS, Aletaha D, Bijsma JW, et al., for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7. doi: 10.1136/ard.2009.123919
4. Naredo E, Rodrigez M, Campos C, et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2008;59:515–22. doi: 10.1002/art.23529
5. Волков АВ, Осипянц РА. Ультрасонография в ревматологии: возможности применения и перспективы. Научно-практическая ревматология. 2010;(4):36 [Volkov AV, Osipyants RA. Ultrasonography in traumatology: opportunities and prospects of application. Nauchno-prakticheskaya revmatologiya =Rheumatology Science and Practice. 2010;(4):36 (In Russ.)].
6. Newman JS, Laing TJ, McCarthy CJ, et al. Power Doppler sonography of synovitis: assessment of therapeutic response: preliminary observations. Radiology. 1996;198:582–4. doi: 10.1148/radiology.198.2.8596870
7. Geng Y, Han J, Deng X, Zhang Z. Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. Clin Rheumatol. 2014;33:1061–6. doi: 10.1007/s10067-014-2634-y
8. Marks DJ, Holroyd DC, Dimitrov DB, et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-TNF therapy? Arthritis Care Res (Hoboken). 2015 May;67(6):746–53. doi: 10.1002/acr.22552
9. Filippucci E, Iagnocco A, Salaffi F, et al. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis. 2006;65:1433–7. doi: 10.1136/ard.2005.044628
10. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 2004;50:1107–16. doi: 10.1002/art.20123
11. Fukae J, Isobe M, Kitano A, et al. Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint. Rheumatology. 2013;52:523–8. doi: 10.1093/rheumatology/ kes310
12. Hernandez Diaz C, Robles-San Roman M, Vargas A, et al. Subclinical inflammation in rheumatoid arthritis in clinical remission, lack of association between cytokines level and ultrasounddefined synovitis. Ann Rheum Dis. 2014;73 Suppl 2: 655. doi: 10.1136/annrheumdis-2014-eular.4855
13. Алексеева ОГ, Новиков АА, Северинова МВ и др. Динамика уровня биомаркеров и ультразвуковые признаки воспаления у пациентов с ревматоидным артритом. Научно-практическая ревматология. 2015;53(5):485–92 [Alekseeva OG, Novikov AA, Severinova MV, et al. The time course of changes in biomarker levels and the ultrasonic signs of inflammation in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(5):485–92 (In Russ.)]. doi: 10.14412/1995-4484-2015-485-492
14. Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51:117–25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51:117–25 (In Russ.)]. doi: 10.14412/1995-4484-2013-637
15. Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА): результаты лечения 130 больных в течение 12 месяцев. Научно-практическая ревматология. 2014;52:607–614 [Karateev DE, Luchikhina EL, Demidova NV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trial): Results of 12-month treatment in 130 patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):607–614 (In Russ.)]. doi: 10.14412/1995-4484-2014-607-614
16. Fransen J, Stucki G, van Reil P. Rheumatoid arthritis measures. Arthritis Rheum. 2003;49:214–24. doi: 10.1002/art.11407
17. Aletaha D, Nell V, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796–806. doi: 10.1186/ar1740
18. Wakefield R, Balint P, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32:2485–7.
19. Scheel AK, Hermann K-GA, Kahler E, et al. A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2005;52:733–43. doi: 10.1002/art.20939
20. Mandl P, Navarro-Compan V, Terslev L, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2015;74:1327–39. doi: 10.1136/annrheumdis-2014-206971
21. Iagnocco A, Finucci A, Ceccarelli F, et al. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis. Rheumatology (Oxford). 2015;54:1890–6. doi: 10.1093/rheumatology/kev211
22. Ivanac G, Morovic-Vergles J, Brkljacic B. Gray-scale and color duplex Doppler ultrasound of hand joints in the evaluation of disease activity and treatment in rheumatoid arthritis. Croat Med J. 2015;56:280–9 doi: 10.3325/cmj.2015.56.280
23. Scire CA, Montecucco C, Codullo V, et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology. 2009;48:1092–7. doi: 10.1093/rheumatology/kep171
24. Naredo E, Collado P, Cruz A, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Care Res. 2007;57:116–24. doi: 10.1002/art.22461
25. Zufferey P, Brulhart L, Tamborrini G, et al. Ultrasound evaluation of synovitis in RA: correlation with clinical disease activity and sensitivity to change in an observational cohort study. Joint Bone Spine. 2014;8:222–7. doi: 10.1016/j.jbspin.2013.08.006
26. Harman H, Tekeoglu I, Kaban N, Harman S. Factors influencing ultrasonographic remission in patients with rheumatoid arthritis. Rheumatol Int. 2015;35:485–91. doi: 10.1007/s00296-014-3177-x
27. Filippucci E, Iagnocco A, Salaffi F, et al. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis. 2006;65:1433–7. doi: 10.1136/ard.2005.044628
28. Hama M, Uehara T, Takase K, et al. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab –preliminary data. Rheumatol Int. 2012;32:1327–33. doi: 10.1007/s00296-011-1802-5
29. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 2004;50:1107–16. doi: 10.1002/art.20123
30. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis. 2013;72:665–71. doi: 10.1136/annrheumdis-2012-201469
31. Ikeda K, Nakagomi D, Sanayama Y, et al. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents. J Rheumatol. 2013;40:1967–76. doi: 10.3899/jrheum.130556
32. Freeston JE, Wakefield RJ, Conaghan PG, et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis. 2010;69:417–9. doi: 10.1136/ard.2008.106658
33. Foltz V, Gandjbakhch F, Etchepare F, et al. Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum. 2012;64:67–76. doi: 10.1002/art.33312
34. Gaertner M, Mandl P, Radner H, et al. Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum. 203;65:2005–14. doi: 10.1002/art.38016
35. Le Boedec M, Jousse-Joulin S, Ferlet JF, et al. Factors influencing concordance between clinical and ultrasound findings in rheumatoid arthritis. J Rheumatol. 2013;40:244–52. doi: 10.3899/jrheum.120843
36. Mandl P, Kurucz R, Niedermayer D, et al. Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. Rheumatology. 2014;53:2136–42. doi: 10.1093/rheumatology/keu211
37. Jurgens MS, Overman CL, Jacobs JW, et al. Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis. Arthritis Care Res. 2015;67:923–8. doi: 10.1002/acr.22532
38. Da Silva Chakr RM, Brenol JC, Behar M, et al. Is ultrasound a better target than clinical disease activity scores in rheumatoid arthritis with fibromyalgia? A case-control study. PLoS One 2015;10:e0118620. doi: 10.1371/journal.pone.0118620
39. Ghib LJ, Tamas MM, Damian LO, et al. The role of ultrasonography in assessing disease activity in patients with rheumatoid arthritis and associated fibromyalgia. Med Ultrason. 2015;17:339–44. doi: 10.11152/mu.2013.2066.173.ljg
40. Naredo E, Valor L, de la Torre I, et al. Ultrasound joint inflammation in rheumatoid arthritis in clinical remission: how many and which joints should be assessed? Arthritis Care Res (Hoboken). 2013;65:512–7. doi: 10.1002/acr.21869
41. Iwamoto T, Ikeda K, Hosokawa J, et al. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res. 2014;66(10):1576–81. doi: 10.1002/acr.22303
42. Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology. 2014;53:2110–8. doi: 10.1093/rheumatology/keu217
43. Mandl P, Balint PV, Brault Y, et al. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. Arthritis Care Res. 2013;65:879–87. doi: 10.1002/acr.21913
Review
For citations:
Alekseeva O.G., Severinova M.V., Demidova N.V., Aleksandrova E.N., Novikov A.A., Luchikhina E.L., Karateev D.E., Volkov A.V., Nasonov E.L. ASSOCIATION BETWEEN CLINICAL MANIFESTATIONS AND ULTRASONIC SIGNS OF INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2015;53(6):596-602. (In Russ.) https://doi.org/10.14412/1995-4484-2015-596-602